Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015

Abstract Background: Amyotrophic lateral sclerosis (ALS) is a progressive fatal disease with a varying range of clinical characteristics. Objective: To describe the clinical characteristics in a large cohort of ALS participants enrolled in the National ALS Registry. Methods: Data from ALS participants who completed the Registry’s online clinical survey module during 2010–2015 were analyzed to determine characteristics, such as site of onset, associated symptoms, time of symptom onset to diagnosis, time of diagnosis to hospice referral, and pharmacological and non-pharmacological interventions. Results: Of the 1758 participants who completed the survey, 60.9% were male, 62.1% were 50–69 years old, and 95.5% white. Approximately, 72.0% reported initial limb weakness onset of disease, followed by bulbar (22.1%), and trunk/global onset (6.1%). Other symptoms ever experienced included cramps (56.7%), fasciculations (56.3%), and dysarthria (33.0%). The median time between an increase of muscle cramps until an ALS diagnosis was 12 months; limb onset participants had cramps longer preceding diagnosis versus those with bulbar onset. The most frequent interventions used included riluzole (48.3% currently using), wheelchairs/scooters (32.8%), and noninvasive breathing equipment (30.0%). Participants with trunk/global onset were referred to hospice almost four times earlier than others. Conclusions: These data show how ALS clinical characteristics differ widely in a large cohort of participants preceding diagnosis and reflect variations in disease onset, progression, and prognosis. Better characterization of symptom onset may assist clinicians in diagnosing ALS sooner, which could lead to earlier therapeutic interventions.

[1]  C. Stocking,et al.  Home ventilation for amyotrophic lateral sclerosis patients , 1993, Neurology.

[2]  E. Pioro,et al.  Racing against the clock: Recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient , 2009, Annals of neurology.

[3]  J. Trojanowski,et al.  Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis , 2013, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[4]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[5]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[6]  Tracy Peters,et al.  Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014 , 2018, MMWR. Morbidity and mortality weekly report.

[7]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[8]  E. Granieri,et al.  Riluzole and other prognostic factors in ALS: a population-based registry study in Italy , 2018, Journal of Neurology.

[9]  A. Eisen How to improve the diagnostic process , 1999, Journal of neurology.

[10]  K. Boylan Familial Amyotrophic Lateral Sclerosis. , 2015, Neurologic clinics.

[11]  D. K. Horton,et al.  Quantifying a nonnotifiable disease in the United States: the National Amyotrophic Lateral Sclerosis Registry model. , 2014, JAMA.

[12]  W. Kaye,et al.  State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[13]  A. Chiò,et al.  Extensive genetics of ALS , 2012, Neurology.

[14]  Nazem Atassi,et al.  Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[15]  E. Beghi,et al.  Incidence of amyotrophic lateral sclerosis in Europe , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[17]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[18]  M. Cartwright,et al.  Natural history of muscle cramps in amyotrophic lateral sclerosis , 2016, Muscle & nerve.

[19]  W. Kaye,et al.  Evaluating the completeness of the national ALS registry, United States , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[20]  T D Koepsell,et al.  Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.

[21]  R. Vermeulen,et al.  A case-control study of hormonal exposures as etiologic factors for ALS in women , 2017, Neurology.

[22]  C. Coffman,et al.  Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[23]  J. R. Brinkmann,et al.  The natural history of amyotrophic lateral sclerosis , 1993, Neurology.

[24]  D. K. Horton,et al.  The National Amyotrophic Lateral Sclerosis (ALS) Registry. , 2012, Journal of environmental health.

[25]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[26]  A. Chiò,et al.  Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort , 2019, Journal of Neurology Neurosurgery & Psychiatry.

[27]  H. E. Stephens,et al.  National Study of Muscle Cramps in ALS in the USA , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[28]  Jm Charcot,et al.  Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere , 1869 .

[29]  G. Sobue,et al.  Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[30]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[31]  Robert H. Brown,et al.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.

[32]  T. Hanafusa,et al.  Onset and spreading patterns of lower motor neuron involvements predict survival in sporadic amyotrophic lateral sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  R. Gross Extensive genetics of ALS: A population-based study in Italy , 2012 .

[34]  N. Staff,et al.  Autonomic system and amyotrophic lateral sclerosis , 2015, Muscle & nerve.

[35]  H. Askmark,et al.  The ALS/MND prevalence in Sweden estimated by riluzole sales statistics , 2005, Acta neurologica Scandinavica.

[36]  T. Ortel,et al.  Venous thromboembolism: a public health concern. , 2010, American journal of preventive medicine.

[37]  J. Glass,et al.  Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997–2011 , 2013, Neurology. Clinical practice.

[38]  Jessica a. Cohen,et al.  Prevalence of Amyotrophic Lateral Sclerosis — United States, 2015 , 2018, MMWR. Morbidity and mortality weekly report.

[39]  O. Hardiman,et al.  From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohort—a thematic analysis , 2017, BMJ Open.

[40]  D. Fan,et al.  Long-Term Use of Riluzole Could Improve the Prognosis of Sporadic Amyotrophic Lateral Sclerosis Patients: A Real-World Cohort Study in China , 2016, Front. Aging Neurosci..

[41]  M. Turner,et al.  Pattern of spread and prognosis in lower limb-onset ALS , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[42]  Sarah Martin,et al.  The changing picture of amyotrophic lateral sclerosis: lessons from European registers , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[43]  C. Coffman,et al.  The National Registry of Veterans with Amyotrophic Lateral Sclerosis , 2008, Neuroepidemiology.

[44]  A. Al-Chalabi,et al.  Amyotrophic lateral sclerosis: moving towards a new classification system , 2016, The Lancet Neurology.